Nasdaq
$2.40▲ 0.63%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $158.5MShares out 66.0M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
15- 10.2After-hours26.10.03 07:044Ownership#●●●#●●●
Adagene Inc.
Adagene Inc. insider Gu Chunfang reported a change in beneficial ownership of securities as of September 30, 2026. This filing serves as a standard Form 4 disclosure regarding insider shareholdings.…more
$2.40+0.63%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.25After-hours26.09.26 07:234Ownership
Adagene Inc.
Adagene Inc. executive Tam Man Kin filed a Form 4 on September 25, 2026, reporting a change in beneficial ownership of securities effective September 23, 2026. This filing serves as an official disclosure of insider equity movement to the SEC.…more
$2.40+0.63%vs prev closeView filingShare - 9.25After-hours26.09.26 05:156-KKey event
Adagene Inc.
Ms. Chunfang (Vicky) Gu, the Executive Director of Finance at Adagene Inc., has resigned from her position effective September 30, 2026, for personal reasons. She confirmed that there are no disagreements with the Board of Directors and no matters requiring attention from shareholders.…more
$2.40+0.63%vs prev closeView filingShare
14 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 9.22Pre-market26.09.22 21:01#●●●#●●●#●●●
Adagene Receives NMPA Approval for ADG138 IND in China
Adagene has received approval from China's NMPA for its investigational new drug application for ADG138, a bispecific T-cell engager utilizing its proprietary SAFEbody technology. The company plans to initiate a Phase 1 clinical trial for advanced solid tumors in the fourth quarter of 2026.…more
$2.40+0.63%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 9.10Pre-market26.09.10 21:00
●●●●●●●● ●●●●● ●●●●●●
Adagene has selected its first lead candidate under an expanded strategic collaboration with Third Arc Bio, which now includes clinical development funding. While the potential milestone payments have increased, the specific financial terms of the agreement remain undisclosed.…more
$2.40+0.63%vs prev close - 9.9Pre-market26.09.09 21:00
●●●●●●●● ●●●●● ●●●●●●
Adagene has achieved a preclinical milestone in its ADC collaboration with Exelixis, resulting in a $2.0 million payment. While this validates their technology platform, the financial impact is relatively small, leading to a neutral outlook.…more
$2.40+0.63%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report